Vapotherm logo — The only mask-free respiratory support tool- an alternative...

Vapotherm

The only mask-free respiratory support tool- an alternative to NiPPV for treating undifferentiated respiratory distress.

Founded 1999 United States Exeter, United States 285 employees Post-IPO Equity Total: $276.60M Biotechnology, Health Care +2

General Information

Company Name Vapotherm
Founded Year 1999
Location United States Exeter, United States
Founders / Decision Makers
Team member
Employees 285
Industries Biotechnology, Health Care, Manufacturing +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Vapotherm. To contact Vapotherm, visit vapotherm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vapotherm compare?

A PDF of Vapotherm and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vapotherm soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vapotherm

Vapotherm, Inc. is a biotechnology, health care, and manufacturing company founded in 1999, headquartered in the United States. It has pioneered the high flow nasal cannula and its advanced form, Vapotherm high velocity therapy, revolutionizing respiratory support. The Precision Flow® system offers clinicians a reliable tool for multiple patient populations, delivering not only oxygenation but also mask-free respiratory support with the comfort of heated humidified high flow. The company's recent success is evident as it became publicly traded, with its common stock trading on the OTCQX tier of the OTC Markets under the symbol “VAPO”. Vapotherm, Inc. secured a considerable $23.00M Post-IPO Equity investment on 08 February 2023. This latest investment showcases investor confidence in the company's innovative approach to respiratory distress treatment and its potential for further growth and impact.

Business keywords: Respiratory support, High flow nasal cannula, Vapotherm high velocity therapy, Precision Flow system, Medical equipment, Emergency medicine, Intensive care, Publicly traded company, NYSE, Ticker symbol VAPO

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $23.00M -
08 Feb 2023
Post IPO Debt $52.00M 1
CIBC Innovation Banking
26 Oct 2020
Series D $10.00M 5
Gilde Healthcare, Morgenthaler Ventures +3
01 Sep 2018
Series D $45.00M 5
Gilde Healthcare, Morgenthaler Ventures +3
25 May 2017
Series C $30.00M 6
Kaiser Permanente Ventures, Morgenthaler Ventures +4
24 Nov 2015
Series C $20.00M 8
Kaiser Permanente Ventures, Gilde Healthcare +6
13 Jul 2015
Series B $24.00M 8
Kaiser Permanente Ventures, Gilde Healthcare +6
03 Apr 2014
Series A $29.00M 7
Kaiser Permanente Ventures, Morgenthaler Ventures +5
25 Apr 2013
Series F $20.50M 5
Kaiser Permanente Ventures, Cross Creek +3
14 Aug 2008
Series E $11.25M 2
Kaiser Permanente Ventures, QuestMark Partners
01 Nov 2007

View All 13 Funding Rounds

Vapotherm Alternatives & Competitors

View All Alternatives
Vapotherm vs
BMC
BMC China

Become the first choice in respiratory care.

1044 employees
Health Care, Medical Devices
Vapotherm vs

French manufacturer and distributor of medical devices. Int'Air Medical is part of Dahlhausen® Grou...

52 employees
Health Care, Manufacturing
Vapotherm vs

Dedicated to natural breathing by empowering patients to wean off mechanical ventilation and breathe...

Venture round
58 employees
Biotechnology, Health Care

FAQ About Vapotherm

The only mask-free respiratory support tool- an alternative to NiPPV for treating undifferentiated respiratory distress.
Vapotherm was founded in 1999.
Vapotherm is headquartered in Exeter, United States.
Vapotherm operates in Biotechnology, Health Care, Manufacturing and Medical Devices. Its work centres on Respiratory support, High flow nasal cannula, Vapotherm high velocity therapy and Precision Flow system.
Vapotherm has approximately 285 employees.
Vapotherm has completed 13 funding rounds, raising a total of $276.60M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Vapotherm include BMC, Int'​Air Medical, Lungpacer Medical, CoLabs, ImpactoMedical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vapotherm and BMC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vapotherm, https://bouncewatch.com/company/vapotherm, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes